US Material Events SEC 8-K Filings — June 16, 2026

16-06-2026

Hallmark Venture Group, Inc. (HLLK) entered into a Change of Control Agreement dated June 9, 2026, under which Selkirk Global Holdings, LLC and Paul Strickland will transfer all 100,000 Series A Preferred Shares (with super-voting rights) and cause the issuance of 50,000,000 common shares (Acquisition Shares) to Equorix LLC. In exchange, Equorix will deliver an executed Intellectual Property Transfer Agreement from Cho Soon-sik and Sundori Drone Co., Ltd., effectively acquiring control without any cash consideration. The company will be renamed SDR Drone Inc. and will file a comprehensive Form 8-K post-closing. The company is a shell with no operating business, approximately $36,131 in net liabilities, and no employees beyond its sole officer.

• · The Series A Preferred Shares carry super-voting rights (100,000 votes per share) and are convertible into common stock at a ratio of 1:900.
• · No cash, securities, or other consideration will be paid by Transferee to Transferor, the Company, or any other person for the change of control.
• · The company is a Rule 12b-2 shell company with no operating business, no employees other than its sole officer, no subsidiaries, no real or personal property, no leases, no inventory, no customers, and no operating contracts.
• · The company's common stock trades on the OTC Pink (Current Information) tier and is DTC-eligible.
• · The company has received no unresolved comment letters, deficiency notices, or stop orders from the SEC, FINRA, OTC Markets, or any state securities regulator.
• · The closing must occur within 30 days of the Effective Date (June 9, 2026) unless extended by mutual written agreement.

16-06-2026

Urban One, Inc. entered into a new employment agreement with CFO Peter D. Thompson through January 6, 2029, with a base salary of $750,000 and eligibility for annual bonuses up to $396,000 (132% of $300,000 target) plus a $850,000 completion bonus contingent on remediation of material weaknesses. At the June 11, 2026 annual meeting, all six director nominees were elected, the 2026 Equity and Performance Incentive Plan was approved (3,083,564 for, 41,890 against), and PricewaterhouseCoopers LLP was ratified as auditor (3,336,914 for, 2,541 against). However, the company continues to have material weaknesses in internal controls as of December 31, 2025, which must be remediated for the CFO to receive the completion bonus.

• · CFO Peter Thompson's employment agreement runs through January 6, 2029, with a signing bonus of $333,333 subject to pro-rata claw-back if he leaves before term end.
• · The $850,000 completion bonus for CFO is contingent on remediation of material weaknesses identified in the Form 10-K for the period ended December 31, 2025.
• · Class D common stock grants to CFO: $704,250 for each of contract years ending Jan 6, 2026 and Jan 6, 2027; $469,500 for each of contract years ending Jan 6, 2028 and Jan 6, 2029.
• · Performance grants to CFO: target value $234,750 for 2026-2027; target value $469,500 for 2028-2029.
• · At the annual meeting, 216,776 non-votes were recorded for each director election, representing shares not voted.
• · The 2026 Equity and Performance Incentive Plan received 3,083,564 votes for and 41,890 against, with 217,508 abstentions.
• · Ratification of PricewaterhouseCoopers LLP was nearly unanimous: 3,336,914 for, 2,541 against, 3,507 abstentions.
• · Class C and Class D common stock were not entitled to vote on any proposal at the meeting.

16-06-2026

F&G Annuities & Life, Inc. announced executive leadership transitions: CEO Chris Blunt will retire effective June 30, 2026, to focus on his roles as Director and CEO of subsidiary Peak Altitude, which will explore strategic alternatives. President and CFO Conor Murphy will become CEO and President, while Michael Bailey will join as CFO on August 3, 2026, with Mark Wiltse serving as interim CFO until then. The company is at an inflection point, transitioning to a more fee-based, higher-margin, less capital-intensive business, though no specific financial metrics were provided to quantify this shift.

• · Chris Blunt has served as CEO since 2019 and nearly tripled assets under management during his tenure.
• · Conor Murphy joined F&G on April 1, 2025, and became President and CFO on August 7, 2025.
• · Michael Bailey most recently served as Retail CFO of Corebridge Financial and also as CFO of Corebridge Insurance Company of Bermuda.
• · Mark Wiltse has been with F&G since 2016 and served as Chief Accounting Officer since May 2020.
• · The company is transitioning to a more fee-based, higher margin, less capital intensive business model, with disciplined growth in spread-based products.

16-06-2026

At Natera, Inc.'s Annual Meeting on June 11, 2026, stockholders elected four directors and ratified Ernst & Young LLP as independent auditor for FY 2026. The advisory vote on executive compensation ('Say-on-Pay') passed with 97.96% support, but a proposal to amend the 2015 Equity Incentive Plan (adding 3.2 million shares) received only 78.1% of votes cast in favor, with significant opposition (26.9 million against). Overall, the meeting showed strong shareholder support for governance decisions but notable dissent on equity compensation expansion.

• · Proposal 5 (equity plan amendment) had 26,861,815 votes against and 123,232 abstentions, reflecting notable shareholder opposition.
• · All director nominees were elected; Eric H. Rubin (Class I) received the highest support (98.3% of votes cast).
• · The advisory vote on frequency of Say-on-Pay favored 'One Year' (121.6 million votes vs. 36,823 for Two Years and 972,982 for Three Years).
• · No broker non-votes were present for Proposal 2 (auditor ratification) because it is considered a routine matter.
• · Record date was April 15, 2026, and 130,691,097 of 142,778,493 outstanding shares were represented at the meeting (91.5% turnout).

16-06-2026

FiscalNote Holdings, Inc. entered into a letter agreement with GPO FN Noteholder, LLC on June 16, 2026, waiving the Company's obligation to deliver a quarterly $2.0 million principal amortization installment due July 1, 2026 under its 7.50% Senior Subordinated Convertible Promissory Note due November 13, 2029. The waived amount will be payable on the Maturity Date. Concurrently, the Company disclosed it continues to evaluate strategic options, including renegotiating or amending existing debt obligations with the help of an external financial advisor, with no assurance of any outcome.

• · The waived principal amortization installment was originally due on July 1, 2026.
• · The 7.50% Senior Subordinated Convertible Promissory Note matures on November 13, 2029.
• · The Company has engaged an external financial advisor to assist in discussions with lenders.
• · Discussions may include amendments, maturity extensions, liability management transactions, exchanges, and other strategic alternatives.
• · There is no assurance that the discussions will result in any outcome on any particular timetable or at all.

16-06-2026

CDT Equity Inc. announced it has restructured its debt by repaying $5,737,500 under its A.G.P. Convertible Loan Note and $555,555.56 under its Ascent Partners Promissory Note, eliminating over $6.3 million in legacy obligations. The company also entered into a new Loan Agreement with JJ Astor for up to $1,460,000 to support working capital, with the first tranche of approximately $268,000 funded. While the debt reduction strengthens the balance sheet and simplifies capital structure, the new facility introduces fresh debt and the company's ability to satisfy conditions for the remaining balance is uncertain.

• · The A.G.P. Convertible Loan Note was originally entered into in December 2024.
• · The Ascent Partners Promissory Note was entered into on March 3, 2026.
• · The JJ Astor Loan Agreement was entered into on June 11, 2026.
• · The balance of the JJ Astor facility is subject to certain conditions the company expects to satisfy in June 2026.
• · Following the repayments, the JJ Astor facility represents the company's sole loan facility.
• · The company is described as a data-driven biopharmaceutical development company focused on therapeutic assets, AI, solid-form chemistry, and asset repositioning.

16-06-2026

BrightSpire Capital, Inc. (BRSP) disclosed via an 8-K filing that its affiliates entered into a definitive agreement to acquire two Albertsons-leased industrial cold storage properties in Tolleson, AZ and Tracy, CA for a total purchase price of $300 million. The transaction involves the assumption of $94 million in mortgage debt and $106 million in mezzanine debt, with a $6 million earnest money deposit. The deal is subject to tenant right-of-first-refusal and a due diligence period ending June 22, 2026, and the properties are currently encumbered by loans from Deutsche Bank.

• · The properties are located at 400 South 99th Avenue, Tolleson, AZ 85353 and 16900 West Schulte Road, Tracy, CA 95377.
• · The leases are dated August 16, 2018, with Albertson's LLC (AZ) and Safeway Inc. (CA), guaranteed by Albertsons Companies, Inc.
• · The due diligence period ends June 22, 2026, and purchasers must deliver a Proceed Notice by that date to continue.
• · If a tenant exercises its right of first refusal, the agreement terminates automatically and the earnest money is returned, with sellers reimbursing purchaser costs up to $500K.
• · The purchase price allocation is set forth in Schedule I of the agreement.
• · The transaction is structured as an asset purchase with assumption of existing loans, not a stock purchase.

16-06-2026

Columbia Sportswear held its 2026 Annual Meeting on June 10, 2026, with 97% of outstanding shares voted. Shareholders approved the Amended and Restated 2020 Stock Incentive Plan, increasing authorized shares by 4.5 million to 9 million, and ratified Deloitte & Touche as auditor. However, the proxy access shareholder proposal was rejected by a wide margin (13.9M for vs 34.0M against), and while executive compensation passed, the stock plan approval saw notable opposition with 6.9 million votes against.

• · All 10 director nominees were elected with strong support; the lowest vote total was Andy D. Bryant with 46,397,053 for (1,567,463 against/withheld).
• · Executive compensation (say-on-pay) passed with 47,847,695 for, 98,053 against, and 18,768 abstentions.
• · The proxy access shareholder proposal was rejected with 13,880,262 for, 34,042,003 against, and 42,251 abstentions.
• · The Amended Plan approval saw 41,006,074 for and 6,931,794 against, indicating significant shareholder dissent (about 14.5% of votes cast excluding broker non-votes).
• · Deloitte & Touche LLP was ratified as independent auditor for 2026 with 49,393,337 for, 205,267 against, and 13,996 abstentions.

16-06-2026

Vivos Therapeutics (VVOS) announced a collaboration agreement with South Palm Cardiovascular Associates (SPCVA), a Florida cardiology practice with ~30,000 patients, to form AIM Florida LLC, a management services organization aimed at diagnosing and treating obstructive sleep apnea (OSA) and insomnia in cardiovascular disease patients. Vivos expects to hold at least 80% of AIM Florida, with SPCVA holding up to 20%, and projects that one fully staffed Sleep Optimization Team could generate over $6,000,000 per year with contribution margins approaching 50%. However, the agreement is preliminary, with definitive documents yet to be finalized, and there is no assurance that the collaboration will achieve its projected revenue, cash flow, or profitability.

• · The collaboration is based on Vivos' successful model from its 2025 acquisition of Sleep Centers of Nevada, but this time Vivos is partnering directly without significant capital outlays.
• · SPCVA is owned by board-certified cardiologists operating a multi-location private cardiology practice in Florida.
• · The initial focus will be on patients in Palm Beach County, Florida.
• · The collaboration is intended to comply with federal and state healthcare laws, including the Anti-Kickback Statute and physician self-referral rules.
• · All clinical decisions and patient care protocols will remain under the authority of licensed healthcare professionals.
• · Vivos' CARE devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first for moderate-to-severe OSA in children ages 6-17.
• · OSA affects over 1 billion people worldwide, with 80% or more undiagnosed.

16-06-2026

Encore Capital Group, Inc. filed an 8-K on June 16, 2026, reporting the adoption of a Third Certificate of Amendment to its Certificate of Incorporation, approved by stockholders at the annual meeting. The amendment limits the personal liability of directors and officers for monetary damages for breach of fiduciary duty to the fullest extent permitted by Delaware law. No financial figures or period-over-period comparisons are included in this filing.

• · The amendment changes Article Eight of the Certificate of Incorporation to limit director and officer liability for monetary damages for breach of fiduciary duty.
• · The amendment was approved by stockholders at the annual meeting held on notice in accordance with Section 222 of the Delaware General Corporation Law.
• · The certificate was signed on June 12, 2026, by Secretary Andrew Asch.
• · The corporation was originally incorporated as MCM Capital Group, Inc. on April 29, 1999.

16-06-2026

SandRidge Energy Inc. held its 2026 Annual Meeting on June 10, 2026, where stockholders approved all four proposals: election of six directors, ratification of Grant Thornton as auditor, advisory approval of executive compensation, and extension of the Omnibus Incentive Plan to 2036. The Board also approved Amendment No. 3 to the Tax Benefits Preservation Plan, extending its expiration from July 1, 2026 to July 1, 2029, subject to stockholder approval at the 2027 Annual Meeting. While all proposals passed, Proposal 4 (Incentive Plan extension) received notable opposition with 1,628,397 votes against and 133,739 abstentions, and director Nancy Dunlap received the lowest support with 2,550,859 votes against.

• · Director Nancy Dunlap received the lowest support among director nominees with 23,262,287 votes for, 2,550,859 against, and 196,229 abstentions.
• · Proposal 4 (Incentive Plan extension) passed with 24,247,239 votes for, 1,628,397 against, and 133,739 abstentions, indicating notable opposition.
• · Ratification of Grant Thornton as auditor passed overwhelmingly with 31,632,466 votes for, 25,031 against, and 65,958 abstentions.
• · Advisory vote on executive compensation passed with 25,190,485 votes for, 729,024 against, and 89,866 abstentions.
• · The Tax Benefits Preservation Plan Amendment No. 3 extends the plan's expiration from July 1, 2026 to July 1, 2029, but requires stockholder approval at the 2027 Annual Meeting.
• · The Omnibus Incentive Plan amendment extends its term to June 10, 2036, effective upon stockholder approval at the 2026 Annual Meeting.

16-06-2026

Prestige Consumer Healthcare Inc. completed the acquisition of the Breathe Right® brand and certain other brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated tax benefits valued at $150 million. The transaction was financed with available cash and a new Term Loan B, and Breathe Right® will become the company’s largest brand, expanding Prestige into a new category. No negative or flat performance metrics were disclosed in this filing.

• · The acquisition was previously announced on March 20, 2026.
• · Breathe Right® was created in the 1990s and is the #1 brand in the nasal strip category.
• · The transaction was financed with available cash on hand and a new Term Loan B.
• · Further details are available in a presentation dated March 20, 2026 on the company's website.

16-06-2026

Space Exploration Technologies Corp. (SpaceX) has entered into a definitive agreement to acquire Anysphere, Inc. (Cursor) for an implied equity value of $60.0 billion, to be paid in shares of SpaceX Class A common stock. The merger is expected to close in the third quarter of 2026, subject to regulatory approvals and other closing conditions. The transaction represents a significant strategic move for SpaceX, though it involves substantial execution and integration risks.

• · The merger consideration will be paid in shares of SpaceX Class A common stock, with the price determined by the volume-weighted average closing price over the seven consecutive trading days immediately preceding closing.
• · The issuance of shares to Cursor stockholders will be exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
• · The Merger Agreement was filed as Exhibit 10.1 to the 8-K, with certain schedules and exhibits omitted per Regulation S-K Item 601(a)(5).
• · SpaceX filed its Registration Statement on Form S-1 on May 20, 2026 (No. 333-296070), indicating it is a public company as of this filing.

16-06-2026

FreightCar America appointed Bradley J. Pickard as an independent director effective June 10, 2026. The Board now comprises nine directors, six of whom are independent. Chairman James R. Meyer highlighted Mr. Pickard's three decades of corporate finance and capital markets experience, particularly in rail, trucking and logistics, as valuable for the Company's continued platform strengthening, aftermarket expansion and disciplined growth.

• · Mr. Pickard is a Managing Director of Republic Partners, LLC (since 2014).
• · Prior leadership roles at Salomon Brothers, Wasserstein Perella and Houlihan Lokey Howard & Zukin.
• · He holds a BA from the University of Michigan and an MBA from the University of Chicago.
• · Company was founded in 1901 and is headquartered in Chicago, Illinois.

16-06-2026

GeneDx Holdings Corp. announced the appointment of Mark Gardner as President, effective June 15, 2026, reporting to CEO Katherine Stueland. Gardner, formerly Senior Vice President of Molecular Genomics and Oncology at Quest Diagnostics, will lead commercial and operations teams to scale efficiently and strengthen execution. The filing contains no financial data or performance metrics, so no positive or negative trends can be assessed.

• · Mark Gardner previously served as Senior Vice President of Molecular Genomics and Oncology at Quest Diagnostics.
• · He also served as CEO of OmniSeq, a precision medicine company acquired by Labcorp.
• · Gardner held senior leadership roles at Thermo Fisher Scientific and Life Technologies.
• · He began his career as a P-3 Orion pilot in the U.S. Navy, rising to Lieutenant Commander.
• · Gardner holds an MBA from The Wharton School, a master's from Georgetown University, and a bachelor's from the U.S. Naval Academy.
• · GeneDx has diagnosed more than 4,800 genetic diseases and published over 1,100 research publications.
• · GeneDx's ExomeDx and GenomeDx tests have FDA Breakthrough Device designation.

16-06-2026

On June 15, 2026, Brady Priest notified Clover Health Investments of his decision to step down as CEO of Clover Care Services, effective July 3, 2026. The company will not appoint a successor; instead, his responsibilities will be reorganized and allocated among existing executive leadership to better integrate the home-care business with broader operations. The departure was not due to any disagreement with the company.

• · The company is a remote-first organization and does not maintain a headquarters.
• · Stockholder communications may be directed to secretary@cloverhealth.com or to The Corporation Trust Company in Wilmington, Delaware.
• · The filing includes forward-looking statements regarding the anticipated benefits of the organizational restructuring.

16-06-2026

AT&T Inc. announced the retirement of Pascal Desroches as Senior Executive Vice President and CFO, effective December 31, 2026, and the appointment of Jennifer Biry as Deputy CFO starting July 6, 2026, with her assuming the CFO role on January 1, 2027. Ms. Biry has prior AT&T experience, including serving as EVP and CFO of WarnerMedia, but the filing also discloses that her stepdaughter is employed by an AT&T subsidiary earning approximately $141,090 in 2025, creating a related-party interest. The transition appears orderly, with a six-month overlap to ensure continuity.

• · Pascal Desroches' retirement announcement was made on June 11, 2026, and is effective December 31, 2026.
• · Jennifer Biry was appointed Deputy CFO on June 15, 2026, effective July 6, 2026.
• · Ms. Biry will become CFO on January 1, 2027, ensuring a six-month transition period.
• · Ms. Biry served as CFO and COO of McAfee since 2022, and previously held senior finance, sales, and strategy roles at AT&T from 1999 to 2022, including EVP and CFO of WarnerMedia (2020–2022).
• · Ms. Biry's stepdaughter is an AT&T subsidiary employee with approximate 2025 compensation of $141,090, a rate comparable to similar positions at the company.

16-06-2026

On June 15, 2026, Century Therapeutics entered into an amended employment agreement with Dr. Chad Cowan, its Chief Scientific Officer, moving him to a part-time role with a reduced annual salary of $296,150 and a pro-rated annual bonus. The change reflects a reduction in executive commitment but does not terminate his position, signaling a potential cost-saving measure while retaining key scientific leadership.

• · Dr. Cowan will continue as CSO on a part-time basis and is eligible for an annual performance-based target bonus on a pro-rated basis.
• · Upon termination or resignation, Dr. Cowan is entitled to all accrued and unpaid base salary through the date of cessation.
• · The A&R Agreement is to be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.
• · No new director appointments or other officer changes were reported.

16-06-2026

Rocket Companies, Inc. closed a $1.5 billion senior notes offering on June 16, 2026, comprising $900 million of 6.125% notes due 2031 and $600 million of 6.500% notes due 2034. Proceeds will be used to repay existing higher-coupon debt, including Rocket Mortgage LLC's 2.875% notes due 2026 and 5.250% notes due 2028, as well as other indebtedness. The offering refinances near-term maturities and extends the company's debt maturity profile, though the new notes carry higher interest rates than the 2.875% notes being redeemed.

• · The 2031 Notes mature on August 1, 2031; interest payable semi-annually on Feb 1 and Aug 1 starting Aug 1, 2026.
• · The 2034 Notes mature on June 15, 2034; interest payable semi-annually on June 15 and Dec 15 starting Dec 15, 2026.
• · The 2026 Rocket Mortgage Notes will be redeemed on June 19, 2026; the 2028 Rocket Mortgage Notes will be redeemed on July 9, 2026.
• · The notes are fully and unconditionally guaranteed on a senior unsecured basis by the company's direct and indirect domestic subsidiaries that are issuers or guarantors under existing senior notes.
• · The indenture includes covenants limiting the company's ability to create liens and to consolidate, merge, or sell substantially all assets, subject to exceptions.
• · Upon a change of control triggering event, the company must offer to repurchase the notes at 101% of principal plus accrued interest.
• · The notes were offered in private transactions under Rule 144A and Regulation S and are not registered under the Securities Act.

16-06-2026

On June 11, 2026, C3.ai director and special advisor Jim H. Snabe notified the company he would take an immediate leave of absence due to his appointment as Special Envoy to the European Commission for Industrial AI. During the leave, he will have no voting rights or duties on the Board or as CEO advisor, and he will not stand for re-election at the 2026 annual meeting. The Board was reduced from 12 to 11 members effective the following day. Mr. Snabe is expected to return after the leave, the duration of which is undetermined.

• · Jim H. Snabe was serving as a special advisor to CEO Thomas M. Siebel prior to the leave
• · The leave is in connection with Snabe's appointment as Special Envoy to the European Commission for Industrial Artificial Intelligence
• · Snabe will not stand for re-election at the 2026 annual stockholder meeting
• · The Board reduction from 12 to 11 directors took effect on June 12, 2026 (the calendar day after the Effective Date)
• · The duration of the leave of absence has not been determined

16-06-2026

On June 10, 2026, Nicholas J. Etten resigned as a director of CEA Industries Inc., effective in June 2026. The filing does not provide any financial data or performance metrics, so no positive or negative trends can be assessed.

• · The resignation was effective June 10, 2026, with the effective date expected in June 2026.
• · No reason for resignation was disclosed in the filing.
• · The filing includes no financial statements or exhibits beyond the cover page.

16-06-2026

Precision BioSciences has amended its loan agreement with Banc of California, extending the Term Loan Maturity Date to December 31, 2029. The amendment, effective June 10, 2026, does not alter other terms of the original agreement, and the company reaffirmed its representations and warranties. No new financial amounts or performance metrics were disclosed in this filing.

• · The amendment extends the Term Loan Maturity Date from an unspecified prior date to December 31, 2029.
• · The amendment was executed on June 10, 2026, and filed with the SEC on June 16, 2026.
• · No changes were made to the loan amount, interest rate, or other financial covenants beyond the maturity date extension.

16-06-2026

LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) announced a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, the market leader in mobile, utility-grade 1 MW battery energy storage systems (BESS). The combined company will be renamed NOMAD Power Solutions, pivoting from clinical-stage biotech to a publicly traded pure-play on deployable power infrastructure. NOMAD has demonstrated strong commercial momentum with revenue growing approximately 175% year-over-year in 2025 and projected growth of approximately 135% in 2026, though the transaction is subject to closing conditions and the company faces execution risks in scaling manufacturing and integrating operations.

• · NOMAD's BESS platform is UL 9540 full-system validated and meets NFPA 855 and IEEE 1547 standards.
• · Permanent BESS projects face development timelines of 2-5 years or longer; NOMAD's mobile architecture bypasses land use entitlements, NEPA/CEQA review, local moratoria, and the multi-year interconnection queue.
• · Approximately 2.3 terawatts of generation and storage capacity are in U.S. interconnection queues.
• · In New York State, 108 local jurisdictions have enacted moratoria or bans on permanent BESS, sidelining approximately 1 GW of permanent battery storage.
• · NOMAD offers equipment sales, rentals, and Energy-as-a-Service offerings.
• · LIXTE's existing biotech operations (LB-100 for cancer, Liora's LiGHT proton therapy system) will continue through its subsidiaries.
• · The transaction is subject to required approvals and closing conditions; ticker symbol change details will be announced later.

16-06-2026

Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, M.D., M.B.A., as a director on June 12, 2026. Dr. Cohen brings over 25 years of healthcare investing and portfolio management experience, including roles at Vida Ventures and JP Morgan Asset Management. He will receive standard non-employee director compensation and a sign-on grant of restricted stock units valued at $887,000 vesting over three years.

• · Dr. Cohen holds an M.B.A. from NYU Stern School of Business and an M.D. from McGill University.
• · He was a lead portfolio manager for the JP Morgan Global Healthcare Fund and co-portfolio manager for the JP Morgan Small Cap Growth Fund.
• · There are no family relationships between Dr. Cohen and any company directors or executive officers.
• · The appointment is effective June 12, 2026.

16-06-2026

VirnetX Holding Corp held its 2026 annual meeting on June 11, 2026, where stockholders approved an amendment to the 2013 Equity Incentive Plan to increase the share reserve by 1,000,000 shares, elected two Class I directors (Kendall Larsen and Gary W. Feiner), ratified Farber Hass Hurley LLP as auditor for FY2026, and approved executive compensation on an advisory basis. However, the equity plan amendment received only 79.8% of votes cast in favor (1,014,822 for vs. 254,814 against), indicating notable shareholder dissent, and broker non-votes were high across all proposals.

• · The equity plan amendment received 254,814 votes against (19.9% of votes cast), indicating significant shareholder opposition.
• · Broker non-votes totaled 1,364,617 on Proposals 1, 3, and 4, representing 51.7% of shares present.
• · Gary W. Feiner received 137,789 votes withheld (10.8% of votes cast for his election), compared to 45,508 for Kendall Larsen.
• · The advisory vote on executive compensation had 93,643 votes against (7.4% of votes cast).
• · Auditor ratification was the most strongly supported proposal with 2,486,962 votes for (94.2% of votes cast).

16-06-2026

American Airlines Group Inc. announced that Vice Chair and Chief Strategy Officer Steve Johnson will retire at the end of 2026, after more than 30 years in the industry. Johnson, who joined America West Airlines in 1995 and later rejoined US Airways in 2009, played a key role in stabilizing the airline's commercial operations, securing a new agreement with Citi, and rebuilding sales and distribution strategy. CEO Robert Isom praised Johnson's contributions, noting he will remain with the company for a few more months before his retirement.

• · Steve Johnson joined America West Airlines in 1995.
• · From 2003 to 2009, he was a partner at Indigo Partners, a private equity firm specializing in airline investments.
• · He rejoined US Airways in 2009.
• · He led the Corporate Affairs organization before being named to his current position.
• · He stepped in to lead the Commercial organization for 18 months during a critical period.

16-06-2026

Norwegian Cruise Line Holdings Ltd. held its annual general meeting on June 11, 2026, with 79.25% of shares represented. Shareholders approved all six proposals, including the election of three Class I directors, the advisory say-on-pay vote (with 85.8% support), the amendment to the 2013 Performance Incentive Plan (increasing authorized shares by 8,807,000 to 56,816,006 and extending the plan to 2036), ratification of PwC as auditor, and a shareholder proposal to declassify the Board. However, the say-on-pay vote saw 14.2% against, and the shareholder proposal received 12.9% against, indicating notable dissent on governance matters.

• · The Restated 2013 Plan extends the expiration date to February 8, 2036.
• · Shareholders approved the declassification of the Board with 235,818,734 votes for, 35,431,208 against, and 930,076 abstentions.
• · The say-on-pay vote received 233,387,448 for, 38,145,401 against, and 647,169 abstentions.
• · The ratification of PwC as auditor received 353,556,052 for, 9,454,489 against, and 841,954 abstentions.
• · The amendment to the 2013 Plan was approved with 262,009,659 for, 9,510,085 against, and 660,274 abstentions.
• · The frequency of future say-on-pay votes was set to annual (265,317,260 for 1 year, 498,761 for 2 years, 5,418,226 for 3 years, 945,771 abstain).

16-06-2026

Dynex Capital appointed Douglas Neal as an independent director to its Board of Directors effective June 15, 2026. Mr. Neal brings extensive investment banking and financial services experience, including over 20 years at BofA Merrill Lynch where he advised on more than $50 billion in transactions, and will serve on the Audit and Compensation Committees. The appointment is expected to support the company's growth and long-term shareholder value, though no specific financial metrics or performance changes were disclosed.

• · Douglas Neal currently manages real estate investments and advises early-stage property technology companies.
• · He served as a Senior Managing Director at BofA Merrill Lynch and was a founding member of the firm's Real Estate Banking Group.
• · He currently serves as an independent board member of Burroughs & Chapin Company, Inc. and as Chairperson of The Boost Pad.
• · Mr. Neal is expected to stand for re-election at the Company's 2027 Annual Meeting of Shareholders.

16-06-2026

Keel Infrastructure Corp. (formerly Bitfarms Ltd) filed an 8-K on June 16, 2026, disclosing a change in its certifying accountant. The company received a letter from PricewaterhouseCoopers LLP (Canada) agreeing with the statements made by the company regarding the auditor change, which is filed as Exhibit 16.1. The filing includes no financial results or period-over-period comparisons, only a procedural update on the auditor resignation/change.

• · Formerly named Bitfarms Ltd until a name change on May 18, 2020.
• · Company is incorporated in Delaware, with fiscal year end December 31.
• · Ticker symbol changed to KEEL (from BITF), trading on NASDAQ.

16-06-2026

Netcapital Inc. entered into a Securities Purchase Agreement with FirstFire Global Opportunities Fund, LLC on June 9, 2026, for a private placement of securities under Section 4(a)(2) and Rule 506(b) of the Securities Act. The company commits to using proceeds for business development and general working capital, with restrictions on activities until the note is paid or converted. The filing includes extensive representations and warranties regarding solvency, environmental compliance, and internal controls, but no specific dollar amounts or conversion terms are disclosed.

• · The agreement is dated June 9, 2026, and filed on June 16, 2026.
• · The Buyer is FirstFire Global Opportunities Fund, LLC, a Delaware LLC based in New York.
• · The Company is a Utah corporation headquartered in Boston, MA.
• · The offering relies on exemption from registration under Section 4(a)(2) and Rule 506(b) of the Securities Act.
• · Proceeds are restricted to business development and general working capital, excluding repayment of insider debt, loans to affiliates, or investments outside current operations.
• · The Company represents it is solvent and will continue as a going concern.
• · The Company represents it is not an investment company under the Investment Company Act of 1940.
• · The Company represents no 'Bad Actor' disqualification events under Rule 506(d).
• · The Company agrees not to change the nature of its business or sell/acquire material assets outside the ordinary course without Buyer consent until the note is paid or converted.
• · No specific dollar amounts, conversion prices, or interest rates are disclosed in the excerpt.

16-06-2026

Allison Transmission Holdings, Inc. announced the repricing of its $508 million Term Loan due 2031, reducing the interest rate margin by 25 basis points to 1.50% per annum for SOFR loans or 0.50% per annum for base rate loans. The repricing is expected to reduce annual cash interest expense by approximately $1.3 million. The maturity date and all other material provisions of the credit agreement remain unchanged.

• · The repricing was completed on June 11, 2026.
• · The Term Loan matures on March 13, 2031.
• · The repricing was executed through an amendment to the second amended and restated credit agreement.
• · Allison operates through two business units: Allison Transmission and Allison Off-Highway Drive & Motion Systems.
• · The company has been in business for over 110 years and operates in over 150 countries.

16-06-2026

Candel Therapeutics, Inc. entered into an employment agreement with CFO Charles Schoch on June 12, 2026, formalizing his continued at-will employment with an annual base salary of $468,600 and a target annual bonus of 40% of base salary. The agreement includes severance provisions of nine months' salary plus target bonus upon qualifying termination, and full acceleration of time-based equity awards upon a qualifying termination within one month before or 12 months after a change in control. No negative or flat metrics are present in this filing.

• · The employment agreement includes customary provisions regarding confidentiality, non-competition, and non-solicitation.
• · Severance eligibility requires execution of a separation agreement and release within 60 days of termination.
• · COBRA premium payments by the company cease upon Mr. Schoch's eligibility for group medical plan benefits under another employer or cessation of COBRA rights.

16-06-2026

HubSpot Inc. held its 2026 Annual Meeting on June 15, 2026, where stockholders approved an amendment to the 2024 Stock Option and Incentive Plan, increasing the reserved shares by 2,300,000, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor. All five Class III director nominees were elected, with Yamini Rangan receiving the highest support (37,499,400 votes for) and Claire Hughes Johnson receiving the lowest (34,396,195 votes for). A non-binding stockholder proposal to allow 10% owners to call special meetings was also approved.

• · Approximately 7.1 million broker non-votes were recorded on most proposals.
• · The proposal to ratify PricewaterhouseCoopers LLP passed with 44,385,046 votes for, 603,404 against, and 33,249 abstentions.
• · The non-binding advisory vote on executive compensation received 34,125,774 votes for and 3,704,399 against (plus 84,116 abstentions and 7,107,410 broker non-votes).
• · The stockholder proposal for special shareholder meeting improvement passed with 30,011,042 votes for and 7,866,837 against.
• · The adjournment proposal received 38,290,605 votes for and 6,682,008 against.
• · All directors were elected to one-year terms ending at the 2027 annual meeting.

16-06-2026

Global Technologies, Ltd. (GTLL) disclosed on June 16, 2026, that its independent auditor, QI CPA LLC, resigned effective the same day. The resignation was not due to any disagreements on accounting principles or reportable events, though the auditor's prior reports included a going concern qualification. The company is now seeking a replacement auditor, which introduces uncertainty regarding financial reporting continuity.

• · QI CPA's audit reports for fiscal years ended June 30, 2025 and June 30, 2024 contained an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern.
• · No disagreements with QI CPA on accounting principles, financial statement disclosure, or auditing scope occurred during the fiscal years ended June 30, 2025 and June 30, 2024, and the subsequent interim period through June 8, 2026.
• · No 'reportable events' as defined in Item 304(a)(1)(v) of Regulation S-K occurred during those periods, except as previously disclosed regarding internal control over financial reporting and disclosure controls and procedures.
• · The company has requested QI CPA to provide a letter to the SEC agreeing with the statements in this filing, which will be filed as Exhibit 16.1.

16-06-2026

Bruce T. Crawford resigned from the Board of Directors of Comtech Telecommunications Corp., effective June 16, 2026, to become president and CEO of AFCEA International. His resignation was not due to any disagreement with the Company or the Board.

• · Mr. Crawford's resignation was previously disclosed in a Form 8-K filed on May 14, 2026.
• · The Company and Board thanked Mr. Crawford for his dedication and years of service.

16-06-2026

Trinity Industries Inc. entered into a Third Amended and Restated Credit Agreement dated June 12, 2026, which amends and restates the existing credit agreement from July 25, 2022. The new agreement provides a $600 million aggregate commitment from a syndicate of lenders led by JPMorgan Chase Bank, N.A. as Administrative Agent, with pricing tied to the company's leverage ratio, ranging from 0.175% to 0.30% for commitment fees and 1.25% to 2.00% for term benchmark loans. The agreement includes customary representations, covenants, and events of default, and replaces the prior facility.

• · The agreement replaces the Second Amended and Restated Credit Agreement dated July 25, 2022.
• · Pricing is determined by a leverage ratio grid with four levels; initial pricing is based on Pricing Level II until a compliance certificate for June 30, 2026 is delivered.
• · The agreement includes a $600 million aggregate commitment with a maturity date defined as the Maturity Date (not explicitly stated in excerpt).
• · Alternative currencies permitted include Canadian Dollars.
• · The agreement contains a keepwell provision (Section 5.10) and financial covenants (Section 6.09).
• · The borrower is a Delaware corporation.

16-06-2026

AES Corp. completed a $1.0B debt offering on June 16, 2026, consisting of $600M of 5.200% Senior Notes due 2029 and $400M of 5.750% Senior Notes due 2033. Proceeds will be used to repay existing indebtedness and for general corporate purposes. The notes were underwritten by a syndicate led by J.P. Morgan and Wells Fargo, issued at slight discounts (99.946% and 99.740% of par). The offering increases AES's leverage; interest on each series is payable semi-annually beginning January 15, 2027.

• · The notes were issued under a Senior Indenture originally dated Dec 8, 1998, supplemented by a ninth supplemental indenture (Apr 3, 2003) and the thirty-second supplemental indenture (June 16, 2026).
• · Interest on both series of notes is payable on January 15 and July 15 each year, beginning January 15, 2027.
• · Make-whole redemption provisions apply before June 15, 2029 for the 2029 Notes and before May 15, 2033 for the 2033 Notes; par redemption applies on or after those dates.
• · Upon a Tax Credit Event, AES may redeem the notes at 101% of principal plus accrued interest.
• · Upon a Change of Control Triggering Event, noteholders can require AES to repurchase the notes at 101% of principal.
• · The underwriters include J.P. Morgan, Wells Fargo, Citigroup, Goldman Sachs, and SMBC Nikko.
• · The filing also includes a legal opinion from Davis Polk & Wardwell LLP (Exhibit 5.1).

16-06-2026

Dell Technologies Inc., through wholly-owned subsidiaries Dell International L.L.C. and EMC Corporation, completed a public offering of $3.0 billion aggregate principal amount of senior notes across three tranches: $1.0 billion of 4.750% notes due 2031, $750 million of 5.000% notes due 2034, and $1.25 billion of 5.250% notes due 2037. The notes are senior unsecured obligations guaranteed by Dell Technologies and certain subsidiaries, and proceeds will be used for general corporate purposes. The issuance increases Dell's debt load but extends maturities and locks in fixed interest rates.

• · The notes are senior unsecured obligations of the Issuers and rank equal with all existing and future senior indebtedness.
• · The notes are guaranteed on a joint and several basis by Dell Technologies Inc., Denali Intermediate Inc., and Dell Inc.
• · Interest on the 2031 Notes accrues at 4.750% per year, payable semi-annually on January 15 and July 15, commencing January 15, 2027.
• · Interest on the 2034 Notes accrues at 5.000% per year, payable semi-annually on February 15 and August 15, commencing August 15, 2026.
• · Interest on the 2037 Notes accrues at 5.250% per year, payable semi-annually on February 15 and August 15, commencing August 15, 2026.
• · The 2031 Notes mature on July 15, 2031; the 2034 Notes mature on February 15, 2034; the 2037 Notes mature on February 15, 2037.
• · Prior to certain dates, the Issuers may redeem the notes at a make-whole premium; thereafter at 100% of principal plus accrued interest.
• · Upon a change of control triggering event, holders may require the Issuers to repurchase the notes at 101% of principal plus accrued interest.
• · The Indenture contains covenants limiting liens on certain assets, mergers, asset sales, and sale-leaseback transactions.

16-06-2026

Travere Therapeutics announced the planned retirement of Chief Research Officer Dr. William Rote, effective February 17, 2027, with his responsibilities to be assumed by Dr. Jula Inrig, who will become Executive Vice President, Head of Research & Development and Chief Medical Officer as of July 1, 2026. The transition includes a consulting arrangement to retain access to Dr. Rote after his retirement, but no negative performance impacts were mentioned in the filing.

• · Dr. Rote's retirement date is February 17, 2027, marking his 10th employment anniversary with the company.
• · Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer, effective July 1, 2026.
• · Dr. Rote is expected to continue serving in his current role through the Retirement Date and assist with the transition.
• · The company expects to enter into a consulting arrangement with Dr. Rote following his retirement.

16-06-2026

Farmers & Merchants Bancshares, Inc. entered into a Second Amendment to its Rights Agreement with Equiniti Trust Company, LLC on June 16, 2026, extending the final expiration date of the rights issued under the agreement to July 29, 2027. The amendment modifies the rights of security holders by prolonging the duration of the existing shareholder rights plan, which was originally set to expire earlier. No financial figures or period-over-period comparisons are provided in this filing.

• · The Rights Agreement was originally dated July 30, 2024, and was first amended on June 17, 2025.
• · The Second Amendment extends the rights expiration date to July 29, 2027, unless further extended or accelerated.
• · The filing does not disclose any financial terms or conditions of the amendment.

16-06-2026

Organogenesis Holdings Inc. held its 2026 Annual Meeting on June 15, 2026, where all 9 director nominees were elected and stockholders approved, on an advisory basis, executive compensation and the ratification of RSM US LLP as auditor for fiscal 2026. The meeting saw 129,564,421 shares of Class A common stock (including shares issuable upon conversion of Series A Preferred) voted. However, director Glenn H. Nussdorf received the most votes withheld (24,250,579) and the lowest votes for (61,049,018), while the advisory vote on executive compensation had 12,722,258 votes against, indicating notable shareholder dissent on those items.

• · Garrett Lustig was re-elected to the board by Series A Convertible Preferred Stock holders via written consent on June 15, 2026.
• · Director Glenn H. Nussdorf received the lowest support with only 61,049,018 votes for and 24,250,579 votes withheld, representing about 28.4% of shares voted withheld.
• · The advisory vote on executive compensation had 12,722,258 votes against, representing approximately 14.9% of shares voted on that proposal.
• · Ratification of RSM US LLP as auditor passed overwhelmingly with 128,421,160 votes for and only 856,933 against.
• · Broker non-votes totaled 44,264,824 for each director election and the executive compensation advisory vote, but zero for the auditor ratification.

16-06-2026

Applied Digital Corp. subsidiary APLD ComputeCo 3 LLC completed a $1.59 billion private offering of 7.000% Senior Secured Notes due 2031, with net proceeds used to fund construction of 150 MW of critical IT load at its Ellendale AI factory campus, repay a bridge loan facility, fund debt service reserves, and pay transaction expenses. The notes bear interest at 7.000% per annum, mature on June 15, 2031, and are subject to semi-annual amortization and various covenants. The company has also provided a completion guarantee for the related projects.

• · The notes were issued at 100.000% of principal amount.
• · Interest is payable semi-annually on June 15 and December 15, beginning December 15, 2026.
• · The notes mature on June 15, 2031, unless earlier redeemed or repurchased.
• · Principal amortizes semi-annually starting on the first Payment Date after the final Commencement Date for all datacenter leases in effect on the Issue Date.
• · The Issuer may redeem notes at its option on or after June 15, 2028, at specified redemption prices.
• · Prior to June 15, 2028, the Issuer may redeem notes at 100% of principal plus a make-whole premium and accrued interest.
• · Up to 40% of the aggregate principal amount may be redeemed with equity offering proceeds before June 15, 2028.
• · Upon a change of control, the Issuer must offer to repurchase notes at 101% of principal plus accrued interest.
• · The Indenture includes covenants limiting additional indebtedness, dividends, investments, liens, asset sales, sale-leaseback transactions, affiliate transactions, and mergers.
• · Applied Digital provided a completion guarantee to fund any shortfall for project completion.
• · The offering was conducted under Rule 144A and Regulation S.
• · The filing is dated June 16, 2026.

16-06-2026

CarParts.com, Inc. (PRTS) entered into a Loan and Security Agreement with First Business Specialty Finance, LLC on June 15, 2026, granting a revolving credit facility (Credit Facility A) secured by substantially all of the company's assets, including accounts, inventory, general intangibles, and deposit accounts. The agreement includes defined collateral accounts and incorporates financial covenants based on EBITDA and Fixed Charges. The company also holds Convertible Notes issued September 10, 2025, totaling $25,000,000 due September 10, 2028, which may constrain liquidity. The filing does not disclose the specific dollar amount of the new credit facility or any financial performance metrics.

• · The credit facility is secured by a first-priority security interest in all of Debtor's personal property, including accounts, inventory, general intangibles (including intellectual property), equipment, and deposit accounts (broad collateral coverage).
• · Three specific Amazon-related collateral accounts are established (Account Nos. 1889-685-14, 1894-369-15, 1341-98-657), indicating Amazon receivables are a key component of the borrowing base.
• · Excluded accounts include cash collateral for letters of credit, foreign bank accounts, zero balance accounts swept daily, payroll/tax accounts, and trust/escrow accounts.
• · The agreement includes a Beneficial Ownership Certification requirement (31 C.F.R. §1010.230).
• · Credit Facility A advances are based on a daily Collateral-Obligation Ratio calculated from Qualified Accounts and monthly Qualified Inventory.
• · The Convertible Notes mature on September 10, 2028.
• · No financial performance data (revenue, EBITDA, Fixed Charges) is provided in this filing, only the legal framework for the loan.

16-06-2026

Ingersoll Rand Inc. held its 2026 annual meeting on June 11, 2026, where stockholders approved all four proposals, including the election of ten directors, ratification of Deloitte & Touche as auditor, advisory approval of executive compensation, and the new 2026 Omnibus Incentive Plan. All director nominees received strong support, with the lowest 'For' vote percentage being 86.6% for William P. Donnelly, while the highest was 99.6% for Jerome Guillen and Marc E. Jones. The meeting had a high turnout of 95.3% of eligible shares.

• · The 2026 Omnibus Incentive Plan was approved with 353,964,877 For votes, 6,254,223 Against, and 299,541 Abstain.
• · Advisory vote on executive compensation passed with 350,614,090 For, 9,557,163 Against, and 347,388 Abstain.
• · Ratification of Deloitte & Touche as auditor for fiscal 2026 passed with 363,304,149 For, 9,594,166 Against, and 67,678 Abstain.
• · Broker non-votes totaled 12,447,352 on all director elections and on proposals 1, 3, and 4.
• · The meeting was held on June 11, 2026, with a record date of April 16, 2026.

16-06-2026

Assertio Holdings, Inc. completed its merger with Zydus Lifesciences Ltd., with stockholders receiving $23.50 per share in cash and the common stock delisted from Nasdaq. As a result of the merger, a Fundamental Change and Make-Whole Fundamental Change were triggered for Assertio's 6.50% Convertible Senior Notes due 2027, giving holders the right to require repurchase at 100% of principal plus accrued interest by July 17, 2026, or to convert each $1,000 principal amount into approximately $382.58 in cash based on a conversion rate of 16.2799 shares per $1,000 principal and the $23.50 merger consideration. The conversion period runs until July 16, 2026, and holders cannot convert notes for which they have submitted a repurchase notice unless they withdraw it.

• · The merger was completed on June 16, 2026, and Assertio will continue as a wholly-owned subsidiary of Zydus Lifesciences.
• · Assertio common stock was delisted from Nasdaq effective June 16, 2026.
• · The Fundamental Change Repurchase Date is July 17, 2026, and holders must deliver repurchase notices by 5:00 p.m. New York City time on July 16, 2026.
• · The conversion period runs until 5:00 p.m. New York City time on July 16, 2026.
• · The Conversion Rate was adjusted to 16.2799 shares per $1,000 principal after giving effect to a 1-for-15 reverse stock split effective December 26, 2025.
• · The conversion consideration is solely cash, not shares, due to the Merger Event.
• · Holders cannot convert Notes for which they have submitted a Fundamental Change Repurchase Notice unless they withdraw it.

16-06-2026

Ashford Hospitality Trust completed the sale of the 119-room Hilton Garden Inn Jacksonville-Deerwood Park for approximately $11.0 million net cash, using $9.5 million of that to repay the related mortgage loan. The pro forma effect shows the hotel contributed only marginal revenues ($1.1M in Q1 2026, $3.6M in FY 2025) and slight operating losses before the gain, so its removal has a modest positive impact on net loss; however, the company still reported a net loss attributable to common stockholders of $(71.0 million) for Q1 2026 and $(209.8 million) for FY 2025 on a pro forma basis.

• · The mortgage loan repaid is secured by a pool of eight hotels, not just the sold property.
• · The company had $252 million in debt associated with hotels in receivership on its balance sheet as of March 31, 2026.
• · Pro forma weighted average common shares outstanding were 5,974 (basic/diluted) for FY 2025 and 6,442 for Q1 2026.
• · The non-recurring gain booked on the sale was approximately $4.03 million for FY 2025 (preliminary).
• · Impairment charges were significant: $67.6M in FY 2025 and $112.6M in Q1 2026 (all retained in pro forma).

16-06-2026

Air T Inc (AIRTP) has entered into a definitive Share Purchase Agreement dated March 8, 2026, to acquire Arena Aviation Partners B.V. through its subsidiary Crestone Air Partners, Inc. The transaction involves the purchase of all outstanding shares of Arena Aviation Partners B.V. from its shareholders, with consideration split between Class A and Class P shares, and includes escrow arrangements and indemnification provisions. The agreement includes customary representations, warranties, and conditions precedent, including the absence of a Material Adverse Effect and receipt of necessary consents.

• · The agreement includes a provision for the treatment of Depositary Receipts (Section 1.4).
• · Consideration is allocated between Class A Shares and Class P Shares (Sections 1.2, 1.3).
• · The transaction includes escrow contributions (Section 1.7) and an indemnity escrow fund (Section 10.6).
• · Conditions precedent include delivery of audited financial statements (Section 7.10) and transfer of aircraft (Section 7.12).
• · The agreement provides for D&O tail insurance (Section 5.8) and E&O tail insurance (Section 5.9).
• · Certain confidential information has been redacted as [***].

16-06-2026

BillionToOne, Inc. held its Annual Meeting of Stockholders on June 10, 2026, where stockholders voted to elect two Class I directors (Oguzhan Atay and Akshay Rai) and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Both proposals passed with overwhelming support, with over 99% of votes cast in favor of each director and over 99% for auditor ratification. No material negative or dissenting votes were recorded, indicating strong shareholder alignment with management.

• · The record date for the Annual Meeting was April 17, 2026.
• · Class B common stock carries 15 votes per share, while Class A common stock carries 1 vote per share.
• · Proposal 2 (auditor ratification) is a routine matter and had no broker non-votes.
• · The filing is an 8-K under Items 5.07 and 9.01, not a material agreement entry (Items 1.01/2.03 were not triggered).

16-06-2026

Matador Resources Co (MTDR) subsidiary MRC Energy Company entered into an Eighth Amendment to its Fourth Amended and Restated Credit Agreement on June 10, 2026, increasing the revolving credit aggregate commitment from $2.25B to $2.75B and reaffirming the borrowing base at $3.25B. The amendment also reallocates revolving credit commitments among existing lenders and adds new lenders, with no defaults or events of default continuing.

• · The amendment was effective as of June 10, 2026, and filed on June 16, 2026.
• · The borrowing base reaffirmation constitutes the Determination Date on or about May 1, 2026.
• · New lenders were added, and existing lenders could increase their revolving credit elected commitments.
• · The amendment includes a post-closing covenant requiring title opinions and mortgages within 45 days to comply with Collateral Coverage Minimum.
• · No defaults or events of default were continuing as of the effective date.

16-06-2026

CEL-SCI Corporation (CVM) announced a best-efforts offering of 2,500,000 shares at $1.00 per share, expecting gross proceeds of $2.5 million, with closing expected on June 16, 2026. The proceeds will fund continued development of Multikine, general corporate purposes, and working capital. The company remains a clinical-stage cancer immunotherapy firm with no approved products, and Multikine's safety/efficacy has not been established.

• · Offering price is $1.00 per share, representing a best-efforts offering.
• · The offering is made under a shelf registration statement on Form S-3 (File No. 333-288515), filed July 3, 2025, and effective August 12, 2025.
• · ThinkEquity is the sole placement agent.
• · Multikine has received Orphan Drug designation from the FDA for neoadjuvant therapy in squamous cell carcinoma of the head and neck.
• · The company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.
• · Multikine has not been licensed or approved for sale by the FDA or any other regulatory agency; its safety and efficacy have not been established.